New Frontiers: ARID3a in SLE
Autor: | M. David Barron, Joshua Garton, Michelle L. Ratliff, Carol F. Webb |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
Adult medicine.medical_treatment Review ARID3a Proinflammatory cytokine 03 medical and health sciences 0302 clinical medicine systemic lupus erythematosus immune system diseases medicine Humans Lupus Erythematosus Systemic interferon alpha Peripheral blood cell Molecular Targeted Therapy Progenitor cell skin and connective tissue diseases lcsh:QH301-705.5 low-density neutrophils Autoimmune disease B-Lymphocytes business.industry Autoantibody General Medicine Dendritic Cells medicine.disease 3. Good health DNA-Binding Proteins Haematopoiesis Adult Stem Cells 030104 developmental biology Cytokine lcsh:Biology (General) plasmacytoid dendritic cells Immunology Stem cell business 030215 immunology Transcription Factors B lymphocytes |
Zdroj: | Cells, Vol 8, Iss 10, p 1136 (2019) Cells |
ISSN: | 2073-4409 |
Popis: | Systemic lupus erythematosus (SLE) is a devastating and heterogeneous autoimmune disease that affects multiple organs, and for which the underlying causes are unknown. The majority of SLE patients produce autoantibodies, have increased levels of type-I inflammatory cytokines, and can develop glomerulonephritis. Recent studies indicate an unexpected but strong association between increased disease activity in SLE patients and the expression of the DNA-binding protein ARID3a (A + T rich interaction domain protein 3a) in a number of peripheral blood cell types. ARID3a expression was first associated with autoantibody production in B cells; however, more recent findings also indicate associations with expression of the inflammatory cytokine interferon alpha in SLE plasmacytoid dendritic cells and low-density neutrophils. In addition, ARID3a is expressed in hematopoietic stem cells and some adult kidney progenitor cells. SLE cells expressing enhanced ARID3a levels show differential gene expression patterns compared with homologous healthy control cells, identifying new pathways potentially regulated by ARID3a. The associations of ARID3a expression with increased disease severity in SLE, suggest that it, or its downstream targets, may provide new therapeutic targets for SLE. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |